IDiyas

For the Inventor, By the Inventor

Lund, Sweden

Antonios Nikitidis

USPTO Granted Patents = 7

 

Average Co-Inventor Count = 5.8

ph-index = 1

Forward Citations = 3(Granted Patents)


Location History:

  • Lund, SE (2011 - 2013)
  • Molndal, SE (2017)
  • Mölndal, SE (2021)

Company Filing History:

goldMedal7 out of 1,500 
 
Astrazeneca Ab
 patents

Years Active: 2011-2021

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents
1. 10961236 - (S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino) thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one as a phosphatidylinositol 3-kinase inhibitor (2021-03-30),
2. 9657001 - Compounds and uses (2017-05-23),
3. 8501784 - 2-pyridone derivatives as neutrophil elastase inhibitors and their use (2013-08-06),
4. 8466284 - Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase (2013-06-18),
5. 8410114 - 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial (2013-04-02),
6. 8114881 - 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial (2012-02-14),
7. 8063073 - 2-pyridone derivatives as neutrophil elastase inhibitors and their use (2011-11-22),

Title: Antonios Nikitidis: Innovator in Pharmaceutical Chemistry

Introduction

Antonios Nikitidis is a prominent inventor based in Lund, Sweden. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target specific biological pathways. With a total of 7 patents to his name, his work has the potential to impact various therapeutic areas.

Latest Patents

One of his latest patents involves a compound known as (S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino)thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one, which acts as a phosphatidylinositol 3-kinase inhibitor. This compound is designed to inhibit PI3K activity, which is crucial in various cellular processes. Additionally, he has developed compounds that are useful in treating diseases where inhibition of leukotriene C synthase is desired, particularly in respiratory diseases and inflammation.

Career Highlights

Antonios Nikitidis is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to focus on innovative solutions in drug development, contributing to the advancement of medical science.

Collaborations

He has collaborated with notable colleagues such as Peter Hansen and Hans Lönn, enhancing the research and development efforts within his team.

Conclusion

Antonios Nikitidis stands out as a key figure in pharmaceutical innovation, with a strong portfolio of patents that reflect his expertise and dedication to improving health outcomes. His contributions continue to shape the future of medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…